Concepts (66)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitamin D | 2 | 2020 | 261 | 1.120 |
Why?
|
| RNA, Long Noncoding | 2 | 2020 | 598 | 0.970 |
Why?
|
| Extracellular Vesicles | 1 | 2024 | 135 | 0.820 |
Why?
|
| Exosomes | 1 | 2024 | 253 | 0.770 |
Why?
|
| Histone Deacetylase 1 | 1 | 2020 | 62 | 0.770 |
Why?
|
| Colorectal Neoplasms | 3 | 2020 | 3578 | 0.730 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 323 | 0.600 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2020 | 507 | 0.580 |
Why?
|
| RNA | 1 | 2019 | 1013 | 0.500 |
Why?
|
| Indoles | 1 | 2020 | 1009 | 0.500 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1331 | 0.470 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 1399 | 0.350 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 1390 | 0.330 |
Why?
|
| Acetylation | 2 | 2020 | 508 | 0.310 |
Why?
|
| Cell Proliferation | 4 | 2021 | 7226 | 0.250 |
Why?
|
| Cell Cycle | 2 | 2020 | 2084 | 0.240 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4638 | 0.240 |
Why?
|
| Endosomes | 1 | 2024 | 109 | 0.230 |
Why?
|
| Pharmaceutical Preparations | 1 | 2024 | 152 | 0.210 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 14551 | 0.210 |
Why?
|
| Peptoids | 1 | 2021 | 4 | 0.210 |
Why?
|
| Peptidomimetics | 1 | 2021 | 26 | 0.200 |
Why?
|
| Histones | 2 | 2020 | 1466 | 0.200 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 80 | 0.200 |
Why?
|
| Virus Internalization | 1 | 2021 | 88 | 0.190 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 10331 | 0.190 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2020 | 41 | 0.180 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 144 | 0.180 |
Why?
|
| Calcitriol | 1 | 2020 | 127 | 0.180 |
Why?
|
| Drug Delivery Systems | 1 | 2024 | 669 | 0.170 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 278 | 0.170 |
Why?
|
| Genes, myc | 1 | 2020 | 358 | 0.160 |
Why?
|
| Gene Editing | 1 | 2020 | 216 | 0.160 |
Why?
|
| Oncogenes | 1 | 2020 | 673 | 0.140 |
Why?
|
| Apoptosis | 2 | 2020 | 7591 | 0.140 |
Why?
|
| Cell Movement | 2 | 2021 | 2466 | 0.130 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 677 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 810 | 0.130 |
Why?
|
| Wound Healing | 1 | 2020 | 815 | 0.130 |
Why?
|
| MicroRNAs | 2 | 2019 | 2947 | 0.130 |
Why?
|
| Imidazoles | 1 | 2020 | 999 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 8873 | 0.120 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 973 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 1443 | 0.110 |
Why?
|
| Gene Expression | 1 | 2020 | 3570 | 0.100 |
Why?
|
| Piperazines | 1 | 2020 | 2101 | 0.100 |
Why?
|
| Humans | 8 | 2021 | 261506 | 0.090 |
Why?
|
| RNA, Messenger | 1 | 2019 | 6150 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 3552 | 0.080 |
Why?
|
| Animals | 2 | 2024 | 59536 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2017 | 2669 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2020 | 5270 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 5178 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4557 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2021 | 515 | 0.050 |
Why?
|
| MCF-7 Cells | 1 | 2021 | 550 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 566 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 931 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 222 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 11538 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 14289 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2019 | 32848 | 0.040 |
Why?
|
| Protein Binding | 1 | 2021 | 3438 | 0.030 |
Why?
|
| Neoplasms | 1 | 2020 | 15193 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 4938 | 0.030 |
Why?
|
| Female | 1 | 2020 | 141928 | 0.020 |
Why?
|